Glucose intolerance and diabetes mellitus in endocrine disorders – Two case reports and a review

Current Diabetes Reviews

Volumn 6, Issue 5, 2010, Pages 266-273

  Adlan, M A ^a   Bondugulapati, L N R ^a   Premawardhana, L D K E ^a  

^a ANEURIN BEVAN UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

Diabetes mellitus; Endocrinopathy; Insulin resistance

Indexed keywords

ALKALINE PHOSPHATASE; AMLODIPINE; CORTICOTROPIN; DEXAMETHASONE; DILTIAZEM; DOPAMINE; DOXAZOSIN MESYLATE; EPINEPHRINE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; LISINOPRIL; METFORMIN; NORADRENALIN; RAMIPRIL; VALSARTAN;

ACROMEGALY; ACUTELY ILL PATIENT; ADRENAL CORTEX ADENOMA; ADRENALECTOMY; ADRENALIN BLOOD LEVEL; ADULT; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTERIAL PH; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT LOSS; CASE REPORT; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; DEHYDRATION; DIABETES MELLITUS; DIABETIC DIET; DIET THERAPY; DISEASE DURATION; DISEASE SEVERITY; DOPAMINE BLOOD LEVEL; DRUG MEGADOSE; ENDOCRINE DISEASE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCAGONOMA; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTHYROIDISM; INSULIN INFUSION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; KETONURIA; LOW DRUG DOSE; MALE; MIDDLE AGED; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; OBESITY; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SMOKING; SOMATOSTATINOMA; TUMOR VOLUME; VIPOMA; X-RAY COMPUTED TOMOGRAPHY; ABDOMINAL RADIOGRAPHY; ADRENAL TUMOR; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ADRENAL GLAND NEOPLASMS; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOCRINE SYSTEM DISEASES; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; RADIOGRAPHY, ABDOMINAL;

EID: 79952117404     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339910793360860     Document Type: Article

References (88)

1. Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 2001; 34: 1429-33.
2. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000; 85: 193-9.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly; epidemiology, pathogenesis, and management. Endocr Rev 2004; 25(1): 102-52.
4. Chen YL, Wei CP, Lee CC, Chang TC. Diabetic ketoacidosis in a patient with acromegaly. J Formos Med Assoc 2007; 106: 88-791.
5. Tran HA, Petrovsky N, Field AJ. Severe diabetic retinopathy: a rare complication of acromegaly. Intern Med J 2002; 32: 52–4.
6. Correa LL, Taboada GF, Van Haute FR, et al. Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR. Arq Bras Endocrinol Metabol 2008; 52: 55-64.
7. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly: Clinical and biochemical features in 500 patients. Medicine 1994; 73: 233-40.
8. Nabarro JDN. Acromegaly. Clin Endocrinol (Oxf) 1987; 26: 481-512.
9. Wass JA, Cudworth AG, Bottazzo GF, Woodrow JC, Besser GM. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 1980; 12: 53-9.
10. Biering H, Knappe G, Gerl H, Lochs H. Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 2000; 27: 27-31.
11. Resmini E, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 2009; 46: 85-95.
12. Urbanik RC, Geurge JM. Cushing’s disease. 18 years’experience. Medicine 1981; 60: 14-24.
13. Nestver JE, Mclanahan MA. Diabetes and adrenal disease. Baillieres Clin Endocrinol Metab 1992; 6: 829-47.
14. Howlett TA, Rees LH, Besser GM. Cushing’s syndrome. J Clin Endocrinol Metab 1985; 14: 911-45.
15. Orth DN. Medical progress: Cushing’s syndrome. N Engl J Med 1995; 332: 791-803.
16. Werbel SS. Ober KP. Phaeochromocytoma update on diagnosis, localization and management. Med Clin North Am 1995; 79: 131-53.
17. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003; 21: 1703-7.
18. Wiesner TD, Buher M, Windgassen M, Paschke R. Improvement of insulin sensitivity after adernalectomy in patients with phaeochromocytoma. J Clin Endocrinol Metab 2003; 88: 3632-36.
19. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome clinical and pathological features in 21 patients. Medicine (Baltimore) 1996; 75: 53-63.
20. Porte D, Sherwin RS, Baron A, Ellenberg M, Rifkin H & Shanahan J, Noujaim S, Holton B. (Eds.) Ellenberg & Rifkin's Diabetes Mellitus. 6th edn. USA: Mcgraw-Hill 2003; 429-30.
21. Franklyn JA. Metabolic changes in thyrotoxicosis. In: Bravreman LE, Utiger RD eds. Werner and Ingbar's The Thyroid, 8th edn. Philadelphia Lipincott Williams and Wilkin. 2000: 667-72.
22. Paul DT, Mollah FH, Alam MK, Fariduddin M, Azad K, Arslan MI. Glycemic status in hyperthyroid subjects. Mymensingh Med J 2004; 13: 71-5.
23. Loffler J, Blanc MH. Diabetes secondary to endocrine disease. Rev Med Suisse Romande 1995; 115: 721-6.
24. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from analysis of 145 cases. Am J Surg 1964; 107: 159-72.
25. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009; 53: 605-10.
26. Khaleeli AA, Johnson JN, Taylor WH. Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathy-roidectomy. Diabetes Metab Res Rev 2007; 23: 43-8.
27. Taylor WH, Khaleeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 2001; 17: 175-80.
28. Ljunghall S, Palmer M, Akerstrom G, Wide L. Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidec-tomy. Eur J Clin Invest 1983; 133: 73-7.
29. Cejkova P, Fojtikova M, Cerna M. Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 2009; 9: 23-7.
30. Hanly EJ, Cooper M, Marohn MR, Kundrotas LW, Charles J Y, Gross S D. Somatostatinomas. E Medicine 2006. Available online: [http://emedicine.medscape.com/article/] 182841 (Accessed on 18.04.2010).
31. Pickup, JC. & Williams, G. (eds.) Text book of Diabetes. 3rd edn. Oxford: Blackwell Science 2003; 27: 27.10-27.11.
32. Petersenn S, Buchfelder M, Gerbert B, et al. Participants of the German Acromegaly Register. Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register. Clin Endocrinol (Oxf) 2009; 71: 400-5.
33. Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin C. N Engl J Med 1979; 301: 1138-42.
34. Potenza M, Via MA, Yanagisawa RT. Excess thyroid hormone and carbohydrate metabolism. Endocr Pract 2009; 15: 254-62.
35. Kim DM, Ahn CW, Kim KR, et al. Duodenal somatostatinoma associated with diabetic ketoacidosis presumably caused by soma-tostatin-28 hypersecretion. J Clin Endocrinol Metab 2005; 90: 6310-5.
36. Douma S, Petidis K, Kartali K, Mahera K, Sabanis C, Zamboulis C. Pheochromocytoma presenting as diabetic ketoacidosis. J Diab Compl 2009; 2: 295-6.
37. Bloom SR, Polak JM. Glucagonoma syndrome. Am J Med (suppl) 1982; 5B: 25-36.
38. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to post receptor defect of insulin action. J Clin Endocrinol 1982; 54: 131-8.
39. Fowwelin J, Attvall S, Von schenck H, Smith U, Lager I. Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 1991; 34: 500-6.
40. Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man mechanisms of insulin resistance, impaired suppression of glucose production and impaired stimulation of glucose utilization. Diabetes 1982; 31: 663-9.
41. David BS, Kitt FP, Gerald IS. Mechanism of Insulin Resistance in Humans and Possible Links With Inflammation. Hypertension 2005; 45: 828-33.
42. Hansen I, Tsalikian E, Beufrere B, et al. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. AmJ Physiol 1986; 250: E269-73.
43. Cryer PE, Catecholamines, phaeochromocytoma and diabetes. Diabetes Rev 1993; 1: 309-17.
44. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome clinical and pathological features in 21 patients. Medicine (Baltimore) 1996; 75: 53-63.
45. Baxter JD, Rousseau GG. Glucocorticoid hormone action: An overview. In; Baxter JD, Rousseau GG, eds. Glucocorticoid hormone action. New York: Springer 1979: 25-49.
46. Colwell JA. Inhibition of insulin secretion by catecholamines in phaeochromocytoma. Ann Intern Med 1969; 71: 251-6.
47. Buckanan KD. APUDomas and diabetes mellitus. Bailliere’s Clin Endocrinol Metab 1992; 6: 899-909.
48. Bloom SR, Polak JM, Pearse AGE. Vasoactive intestinal peptide and watery diarrhoea syndrome. Lancet 1973; 2: 14-6.
49. Raboudi N, Arem R, Jones RH, et al. Fasting and postabsorptive hepatic glucose and insulin metabolism in hyperthyroidism. Am J Physiol 1989; 256: 159-66.
50. Holdsworth CD, Besser GM, Influence of gastric emptying-rate and insulin response on oral glucose tolerance tests in thyroid disease. Lancet 1968; 2: 700-2.
51. Huang S, Czech MP.The GLUT4 glucose transporter. Cell Metab 2007; 5: 237-52.
52. Dimitriadis G, Leighton B, Parry-Billings M, et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 1997; 321: 707-12.
53. Ewart HS, Somwar R, Kip A. Dexamethasone stimulates the expression of GLUT1 and GLUT4 proteins via different signalling pathways in L6 skeletal muscle cells. FEBS Lett 1998; 42: 120-24.
54. Smith TR, Elmendorf JS, David TS, et al. Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Am J Physiol 1997; 272: 1071-80.
55. Sasaki-Suzuki N, Arai K, Ogata T, et al. Growth hormone inhibition of glucose uptake in adipocytes occurs without affecting GLUT4 translocation through an Insulin receptor substrate-2-phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem 2009; 284: 6061-70.
56. Fonseca V, Bouloux PM. Phaeochromocytoma and paragan-glionoma. Bailliere’s Clin Endocrinol Metab 1993; 7: 509-44.
57. Brown MJ, Allison DJ, Jenner DA, Lewis PJ, Dollery CT. Increased sensitivity and accuracy of phaeochromocytoma diagnosis achieved by plasma adrenaline estimation and pentolinium-suppression rest. Lancet 1981; 1: 174-7.
58. Vance JE, Buchanan KD, O’Hara D. Williams RH, Porte DJ. Insulin and glucagon responses in subjects with phaeochromocytoma. J Clin Endocrinol Metab 1969; 29: 911-16.
59. Bravo EL, Gifford RW: Current Concepts. Pheohromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311: 1303.
60. Wenstein SP, O’Boyle E, Fisher M, Haber RS. Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. Endocrinology 1994; 135: 649-54.
61. Shen DC, Davidson MB, Kuo SW, Sheu WH. Peripheral and hepatic insulin antagonism in hyperthyroidism. J Clin Endocrinol Metab 1988; 66: 565-9.
62. Bech K, Damsbo P, Eldrup E, et al. Beta-cell function and function and glucose and lipid oxidation in Grave’s disease.Clin Endocrinol (Oxf) 1996; 44: 59-66.
63. Wu TJ, Huang SM, Taylor RL, Kao PC. Abnormal proinsulin levels in thyroid dysfunction measured by a sensitive proinsulin immunochemiluminoassay. Ann Clin Lab Sci 1988; 25: 82-7.
64. Krejs GJ, Orci L, Conlon JM, et al. Somatostatinoma syndrome; biochemical, morphologic and clinical features. N Engl J Med 1979; 301: 285-92.
65. Schusdziarra VZ. Glucagonoma-somatostatinoma. Gastroenterol Suppl 1999; 1: 33-5.
66. Loffler J, Blanc MH. Diabetes secondary to endocrine disease. Rev Med Suisse Romande 1995; 115: 721-6.
67. Ischimori M, Takeda N, Okumura S, et al. Increased insulin sensitivity in patients with aldosterone producing adenoma. Clin Endocrinol (Oxf) 1994; 414: 33-8.
68. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965; 273: 1135-43.
69. Fallo F, Federspil G, Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Curr Diab Rep 2008; 8: 42-7.
70. Prager R, Kovarik J, Schernthaner G, Woloszczuk W, Willvonse-der R. Peripheral insulin resistance in primary hyperparathyroidism. Metabolism 1983; 32: 800-5.
71. Kumar S, Olukoga AO, Gordon C, et al. Impaired glucose tolerance and insulin insert insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994; 40: 47-53.
72. Kautzky-Willer A, Niederle B, Schernthaner G, Prager R. Diabetes mellitus and carbohydrate metabolism in primary hyperparathyroidism. Wien Klin Wochenschr 1993; 105: 158-62.
73. Prager R, Schernthaner G, Kovarik J, et al. Primary hyperparathyroidism is associated with decreased insulin receptors binding and glucose intolerance. Calcif Tissue Int 1984; 36: 253-8.
74. Gerl H, Pirlich M, Lochs H. Improvement of diabetes mellitus after excision of a parathyroid adenoma. Wien Klin Wochenschr 1998; 110: 841-4.
75. Mak RH, Bettinelli A, Turner C, Haycock GB, Chantler C. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab 1985; 60: 229-33.
76. Katz EJ, Donald RA, Beaven DW, Espiner EA. Lack of effect of hyperprolactinemia on glucose disposal and insulin secretion in patients with prolactinomas. Horm Metab Res 1981; 13: 667-9.
77. Schernthaner G, Prager R, Punzengruber C, Uugar A. Severe hy-perprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985; 28:138-42.
78. Vigas M, Klimes I, Jurcovicova J, Jezova D. Acute elevation of endogenous prolactin does not influence glucose homeostasis in healthy men. Physiol Res 1993; 42: 341-5.
79. Moller N, Schmitz O, Jourgensen JO, et al. Basal-and insulin stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992; 74: 1012-19.
80. Col V, De Canniere L, Collard E, Michel L, Donkier J. Laparoscopic adrenalectomy for Pheochromocytoma: endocrinological and surgical aspects of a new therapeutic approach. Clin Endocrinol (Oxf) 1999; 50: 121-5.
81. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglyce-mic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-8.
82. Lupi R, Dell Guerra S, Fierabracci V, et al. Lipotoxcicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002; 51(Suppl 1): S 134-7.
83. Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegally converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003; 149: 521-7.
84. Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem pharmacol. 2000; 59: 887-90.
85. Baily CJ, Wilcock C, Scarpello HB. Metformin and the intestine. Diabetologia 2008; 51: 1552-53.
86. Moller N, Schmitz O, Jourgensen JO, et al. Basal-and insulin stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992; 74: 1012-19.
87. Col V, De Canniere L, Collard E, Michel L, Donkier J. Laparoscopic adrenalectomy for Pheochromocytoma: endocrinological and surgical aspects of a new therapeutic approach. Clin Endocrinol (Oxf) 1999; 50: 121-5.
88. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisolm DJ. Impact octreotide, a long acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992; 36: 271-9.